certolizumab pegol Clinical Research Trials

Optimizing Cimzia in Crohn's Patients

The purpose of this study is to determine if increasing the dose and/or dosing frequency of certolizumab pegol (Cimzia) is effective in regaining and optimizing response in patients with

cimzia

certolizumab pegol

60 views
08 Nov, 2020
1 location

Pediatric Arthritis Study of Certolizumab Pegol

A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course

30 views
17 Dec, 2020
46 locations

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with

tuberculosis

bacillus calmette-guerin

cimzia

purified protein derivative

interferon gamma release assay

54 views
13 Jan, 2021
8 locations

A Study to Evaluate the Efficacy Safety and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12

9 views
14 Jan, 2021
35 locations

Assessing Patient Confidence in Biologic Medications

cycle. Examples of biologic medications commonly used in dermatology include tumor necrosis factor-alpha (TNF-alpha), blockers/inhibitors (etanercept, infliximab, certolizumab pegol, golimumab

secukinumab

tumor necrosis factor alpha

ixekizumab

tumor necrosis factor

etanercept

67 views
31 Dec, 2020
1 location

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.